Safety and Efficacy of Apixaban For Therapeutic Anticoagulation in Critically Ill ICU Patients with Severe COVID-19 Respiratory Disease.

导出 LinkOut

翻译打印收藏纠错

作者： Eric,Wenzler ^[1] ; Monaz H,Engineer ^[1] ; Maidah,Yaqoob ^[2] ; Scott T,Benken ^[1]

作者单位： Department of Pharmacy Practice, College of Pharmacy, University of Illinois at Chicago, Chicago, Illinois, United States. ^[1] Division of Pulmonary, Critical Care, Sleep, and Allergy, Department of Medicine, University of Illinois at Chicago, Chicago, Illinois, United States. ^[2]

关键词 COVID-19 SARS-CoV-2 apixaban coagulopathy thrombosis

DOI 10.1055/s-0040-1720962

PMID 33244512

发布时间 2020-11-28

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

TH open

2020年4卷4期

e376-e382页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Safety and Efficacy of Apixaban For Therapeutic Anticoagulation in Critically Ill ICU Patients with Severe COVID-19 Respiratory Disease.

TH open

相似文献

TH open

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Safety and Efficacy of Apixaban For Therapeutic Anticoagulation in Critically Ill ICU Patients with Severe COVID-19 Respiratory Disease.

TH open

相似文献

TH open

相关期刊

检索历史清除